Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.
Copyright: © 2026 Notini et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.